Interventional Radiology Imaging

What Is the Initial Therapy for a Saddle PE With Normal RV Function?

·
What Is the Initial Therapy for a Saddle PE With Normal RV Function?

A 45-year-old patient presents to the emergency department with acute-onset pleuritic chest pain and shortness of breath. A CT Angiogram (CTA) confirms the clinical suspicion: a large, acute saddle pulmonary embolism (PE) straddling the main pulmonary artery bifurcation. While the anatomical finding is alarming, the patient is hemodynamically stable with a normal blood pressure, a normal troponin level, and a reassuring RV/LV ratio of 0.9 on the CTA. The immediate question for the clinical team is whether the high-risk location of the clot necessitates aggressive intervention, or if the patient’s stable physiology allows for a more conservative approach. This article addresses the specific American College of Radiology (ACR) Appropriateness Criteria for this exact scenario, where the recommended initial therapy is Anticoagulation, rated as Usually appropriate.

Who Fits This Clinical Scenario for Saddle Pulmonary Embolism?

This guidance applies to a very specific subset of patients with acute pulmonary embolism. The key is the discordance between a high-risk anatomical finding (the saddle embolus) and low-risk physiological parameters.

Inclusion criteria for this workflow:

  • Adult patient
  • Acute saddle pulmonary embolism confirmed on imaging (e.g., CTA).
  • Hemodynamic stability: No hypotension (defined as systolic blood pressure remaining above 90 mmHg).
  • No evidence of right ventricular (RV) strain: This is confirmed by both imaging (RV/LV ratio ≤ 0.9 on CTA) and biomarkers (normal troponin level).

Exclusion criteria (patients who require a different workflow):

  • Patients with hypotension: A saddle PE with sustained hypotension (systolic BP < 90 mmHg for more than 15 minutes) is classified as a massive PE. This is a life-threatening emergency requiring immediate consideration of more aggressive therapies like systemic thrombolysis or surgical embolectomy.
  • Patients with RV strain: A saddle PE with evidence of RV strain (e.g., RV/LV ratio > 0.9, elevated troponin or BNP, or specific findings on a formal echocardiogram) is classified as a submassive (or intermediate-risk) PE. These patients may be candidates for advanced therapies like catheter-directed thrombolysis.
  • Patients with contraindications to anticoagulation: If a patient has an active major bleed or another absolute contraindication, this entire workflow changes, often requiring consultation for an IVC filter or other interventions.

What Diagnoses Are You Working Up in This Scenario?

In this clinical scenario, the diagnosis of acute pulmonary embolism has already been established by CT angiography. The critical “workup” is not diagnostic but prognostic, focusing on risk stratification to guide the intensity of initial therapy. The presence of a saddle embolus automatically places the patient in a higher-risk category anatomically, but the clinical decision hinges on determining their physiological risk category.

Massive (High-Risk) PE: This is the most immediate concern to rule out. It is defined by the presence of sustained hypotension, cardiogenic shock, or cardiac arrest. A saddle embolus can certainly cause this, but in this scenario, the patient’s normal blood pressure explicitly excludes this classification. The primary goal of the initial assessment is to confirm hemodynamic stability.

Submassive (Intermediate-Risk) PE: This is the next most critical category to differentiate. Submassive PE is defined by the presence of right ventricular dysfunction in the absence of hypotension. Evidence for RV dysfunction can come from imaging (RV dilatation on CTA or echocardiogram), cardiac biomarkers (elevated troponin or BNP), or EKG changes. This scenario’s criteria—a normal RV/LV ratio and a normal troponin—specifically place the patient outside this category.

Low-Risk PE: Despite the intimidating anatomical location of the clot, this patient’s physiological parameters place them in the low-risk category. The core clinical challenge is reconciling the “scary” image of a saddle embolus with the reassuring clinical data. The evidence-based approach prioritizes physiology over anatomy in this specific context, guiding therapy toward standard anticoagulation while acknowledging the need for close monitoring.

Why Is Anticoagulation the Recommended Initial Therapy for a Stable Saddle PE?

For an adult with an acute saddle pulmonary embolism who is hemodynamically stable and shows no signs of right heart strain, the ACR panel designates Anticoagulation as Usually appropriate. The rationale is grounded in balancing the efficacy of treatment against its potential harm. The primary goal is to prevent new thrombus formation and allow the body’s own fibrinolytic system to gradually dissolve the existing clot, thereby restoring pulmonary blood flow.

In a stable patient, standard anticoagulation (e.g., with heparin followed by an oral agent, or with a direct oral anticoagulant) is highly effective at achieving this goal. It arrests the thrombotic process and prevents the embolus from enlarging or new emboli from forming, which is the main driver of clinical deterioration.

The ACR rates more aggressive therapies as Usually not appropriate for this specific patient profile because their significant risks are not justified by the patient’s stable condition.

  • Systemic Thrombolysis: This therapy carries a substantial risk of major bleeding, including life-threatening intracranial hemorrhage. Its use is reserved for patients with massive PE, where the immediate risk of death from circulatory collapse is high enough to outweigh the serious bleeding risk. In a stable patient, this risk-benefit ratio is unfavorable.
  • Catheter-Directed Therapy (CDT): This involves placing a catheter into the pulmonary arteries to deliver a lower dose of thrombolytic medication directly into the clot or to mechanically break it up. While safer than systemic thrombolysis, it is still an invasive procedure with potential complications like access site hematoma, pulmonary artery injury, and bleeding. CDT is typically considered for patients with submassive PE who show evidence of RV strain, as they are at higher risk of decompensation. For a patient with normal RV function, the added benefit of CDT over standard anticoagulation is not established and does not warrant the procedural risk.

Surgical embolectomy and extracorporeal membrane oxygenation (ECMO) are even more invasive and are reserved for the most severe cases of massive PE, often when thrombolysis is contraindicated or has failed. They are clearly designated as Usually not appropriate for this stable patient.

What’s Next After Anticoagulation? Downstream Workflow

Initiating anticoagulation is the first step, but the downstream workflow involves careful monitoring and planning for long-term management. The key is to watch for any signs of clinical deterioration that might indicate a failure of initial therapy.

  • If the patient remains stable: The patient should be admitted to a monitored setting (e.g., a step-down unit or telemetry floor) for close observation of vital signs, oxygen saturation, and any new symptoms for at least the first 24-48 hours. The choice of anticoagulant (e.g., IV heparin drip, LMWH, DOAC) will depend on institutional protocols and patient-specific factors like renal function. The focus shifts to determining the appropriate duration of anticoagulation (typically 3-6 months or longer, depending on whether the PE was provoked or unprovoked) and planning for a safe discharge.
  • If the patient deteriorates: If the patient develops hypotension, worsening tachycardia, hypoxia, or other signs of RV strain (which would be a new development), their risk category has changed. They have now escalated from a low-risk PE to a submassive or massive PE. This constitutes a clinical emergency. The patient’s management plan must be immediately reassessed, and a multidisciplinary Pulmonary Embolism Response Team (PERT) should be activated if available. This would trigger re-evaluation for the advanced therapies that were initially deemed inappropriate, such as catheter-directed therapy or systemic thrombolysis.
  • If the diagnosis is later questioned: While a CTA is highly specific, in very rare or complex cases with confounding findings, further evaluation may be needed. However, for a clear-cut saddle embolus, the diagnosis is secure, and the focus remains on therapeutic management and monitoring the response.

Pitfalls to Avoid (and When to Get Help)

Managing a patient with a saddle PE requires vigilance, even when they appear stable initially. Several pitfalls can lead to poor outcomes.

  • Underestimating the potential for decompensation: Do not be falsely reassured by the initial stability. A large clot burden means the patient has limited cardiopulmonary reserve. A small, new clot or a shift in the existing one can trigger rapid deterioration. Close monitoring in an appropriate hospital setting is crucial.
  • Discharging the patient too early: While some very low-risk, small PEs can be managed in the outpatient setting, a saddle PE, even in a stable patient, warrants an initial period of inpatient observation.
  • Delaying anticoagulation: Once the diagnosis is made and there are no contraindications, anticoagulation should be started immediately. Delays can allow for clot propagation and increase the risk of adverse events.
  • Failing to investigate the cause: After stabilizing the patient, it is important to consider the underlying cause of the PE (e.g., recent surgery, malignancy, inherited thrombophilia) to guide the long-term duration of therapy and prevent recurrence.

If the patient develops any signs of hemodynamic instability, worsening respiratory status, or new signs of right heart strain, this is a critical event. Escalate immediately by activating your institution’s rapid response or PERT team and involving critical care and interventional radiology or cardiology specialists.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants and management strategies, or to explore the technical details of imaging procedures, the following resources provide authoritative guidance.

Frequently Asked Questions

Does a ‘saddle PE’ automatically mean the patient needs thrombolysis?

No. While a saddle PE represents a large clot burden in a critical location, the decision for aggressive therapy like thrombolysis is based on the patient’s physiological state, not just the anatomy. If the patient is hemodynamically stable with no evidence of right heart strain (normal RV/LV ratio, normal troponin), standard anticoagulation is the recommended initial therapy.

Why is the RV/LV ratio on CTA so important in this scenario?

The right ventricle to left ventricle (RV/LV) diameter ratio is a key indicator of right heart strain. An enlarged RV (ratio > 0.9 or 1.0) suggests it is struggling to pump against the high pressure caused by the pulmonary clot. A normal ratio in a patient with a saddle PE is a reassuring sign that the heart is currently compensating well, supporting the decision to start with anticoagulation alone.

If the troponin is normal, can I be sure there is no right heart strain?

A normal troponin is a very strong negative predictor of significant myocardial strain and adverse outcomes in acute PE. While a formal echocardiogram is the gold standard for assessing RV function, the combination of a normal troponin and a normal RV/LV ratio on CTA provides high confidence that the patient is at low risk for imminent decompensation and can be safely managed with anticoagulation.

Should this patient be admitted to the ICU?

Not necessarily. A patient with a stable saddle PE does not automatically require an ICU bed. However, they do require admission to a setting with continuous cardiac and pulse oximetry monitoring, such as a telemetry or step-down unit. This allows for early detection of any potential deterioration. An ICU admission would be warranted if the patient had any hemodynamic instability, high oxygen requirements, or other signs of impending decompensation.

What if the patient’s blood pressure starts to drop after starting anticoagulation?

If a patient with an initially stable saddle PE develops hypotension, their risk classification immediately changes to massive (high-risk) PE. This is a medical emergency. You must rapidly reassess the patient, activate your institution’s Pulmonary Embolism Response Team (PERT) or rapid response team, and consider escalating to advanced therapies like systemic thrombolysis or catheter-directed intervention.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026